Clinical trial
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00477269 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- January 31, 2014
- Enrollment
- 59 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.